

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q95661

Kazuyuki OHMOTO, et al.

Appln. No.: Based on PCT/JP04/019753

Confirmation No.: Unknown

Group Art Unit: Unknown

Filed: June 26, 2006

Examiner: Unknown

For: PREVENTIVE AND/OR THERAPEUTIC AGENT FOR DISEASE IN WHICH
MITOCHONDRIAL BENZODIAZEPHINE RECEPTOR PARTICIPATES

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

A copy of an International Search Report in a counterpart application is submitted herewith. The USPTO should receive copies of the references cited in the International Search Report from the International Bureau. Applicant will furnish any missing references upon request.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after

10/584280
AP3 Rec'd PCT/PTO 26 JUN 2006

INFORMATION DISCLOSURE STATEMENT

U.S. Appln. No.: Based on PCT/JP04/019753

Attorney Docket No: Q95661

filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign language documents, Applicant encloses herewith a copy of a Communication from a foreign patent office in a counterpart application citing such documents (International Search Report for PCT/JP04/019753 dated March 22, 2005), together with an English-language version (if not already included) of at least that portion of the Communication indicating the degree of relevance found by the foreign patent office.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

for John Callahan Reg. No. 32,607
Mark Boland
Registration No. 32,197

Date: June 26, 2006

10/58428U

AP3 Rec'd PCT/PTO 26 JUN 2006

MODIFIED PTO/SB/08 A & B (08-03)

Substitute for Form 1449 A & B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	Based on PCT/JP04/019753
Confirmation Number	Unknown
Filing Date	June 26, 2006
First Named Inventor	Kazuyuki OHMOTO
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	Q95661

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US 6,410,533	B1	06-25-2002	Genzyme Corp.
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			
		WO	2003/030937	A1	04-17-2003	ONO PHARMACEUTICAL CO., LTD.	
		WO	2003/068753	A1	08-21-2003	ONO PHARMACEUTICAL CO., LTD.	
		JP	11-171865	A	06-29-1999	Yoshitomi Pharmaceutical Industries Ltd.	
		JP	2002-510683	A	04-09-2002	AUSTALIAN NUCLEAR SCIENCE & TECHNOLOGY ORGANIZATION	
		JP	10-130150	A	05-19-1998	Dainippon Pharmaceutical Co., Ltd.	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		International Search Report for PCT/JP04/019753 dated March 22, 2005	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.